AZD4635 (HTL-1071)

Background Information:

AZD4635 (HTL-1071) is an orally bioavailable, potent and selective A_2A (Adenosine 2A) receptor antagonist, binding to human A_2A
receptor with a Ki value of 1.7 nM, and with > 30-fold selectivity
over other adenosine receptors. High adenosine level in tumors, produced
by stimulating A_2A
receptors, is immune suppressive, which prevents T-cells within the
immune system from being activated thus reduces their ability to destroy
cancer cells. Antagonizing A_2A
receptors can therefore promote the anti-cancer response of T-cells
within the tumour microenvironment. AZD4635 is currently being evaluated
as a monotherapy and in combination with other anti-PDL1 agents in
patients with advanced solid cancers.

APIM050269: AZD4635 (HTL-1071)

CAS No.: 1321514-06-0.
Molecular Formula: C15H11ClFN5.
Molecular Weight: 315.7.
Purity: >99% by HPLC.
QC: HPLC-MS, 1H-NMR, and Quantitative Elemental Analysis.
Solubility: Refer to Certificate of Analysis.
Storage: Refer to Certificate of Analysis.